AI Summary
The combination of lenvatinib and pembrolizumab could be an effective treatment for previously treated advanced B3-thymoma and thymic carcinoma, according to the results presented at the ESMO Congress 2024. The PECATI study showed promising outcomes with a 5-month progression-free survival rate of 88% in 43 patients who received this combination therapy.
Lenvatinib combined with pembrolizumab could be a potential treatment for previously treated advanced B3-thymoma and thymic carcinoma. Jordi Remon Masip (Gustave Roussy, Villejuif, France) presented results from the single-arm phase 2 PECATI study, in which 43 patients with pretreated B3 thymoma and thymic carcinoma were given 20 mg oral lenvatinib daily combined with 200 mg intravenous pembrolizumab in 3-week cycles. The primary endpoint was the 5-month progression-free survival rate (which had to be >68·6% to reject the null hypothesis) and was met: 5-month progression-free survival was 88% (95% CI 73–95).